IFNB1 and multiple sclerosis: In summary, this study demonstrates that both LAQ and IFN-β (Rebif) treatments modulate transcriptional networks related to coagulation, fibrinolysis, and vascular regulation, suggesting a molecular interface between immune and hemostatic pathways in multiple sclerosis.